Core Insights - DURECT Corporation will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025, with CEO James E. Brown leading the presentation [1][2] - The company is focused on developing epigenetic therapies, particularly targeting dysregulated DNA methylation to treat serious conditions like acute organ injury [3] Company Overview - DURECT is a late-stage biopharmaceutical company known for its lead drug candidate, larsucosterol, which inhibits DNA methyltransferases associated with alcohol-associated hepatitis (AH) [3] - Larsucosterol is currently in clinical development for AH and has received Fast Track and Breakthrough Therapy designations from the FDA [3] - The company is also exploring larsucosterol for metabolic dysfunction-associated steatohepatitis (MASH) [3] - DURECT's POSIMIR® (bupivacaine solution) is FDA-approved for infiltration use and utilizes the SABER® platform technology [3] Presentation Details - The presentation is scheduled for February 11, 2025, from 2:00 to 2:30 PM ET, and will be available via webcast [2] - DURECT management will engage in one-on-one investor meetings during the conference [2]
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference